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A B S T R A C T
Individuals suffering from diabetes have an increased risk of developing cardiovascular complications such as
heart failure. Heart failure can be a result of the stiffening of the left ventricle, which occurs when cardiac
fibroblasts become “active” and begin to remodel the extracellular matrix (ECM). Fibroblast “activation” can be
triggered by the AGE/RAGE signaling cascade. Advanced Glycation End products (AGEs) are produced and
accumulate in the ECM over time in a healthy individual, but under hyperglycemic conditions, this process is
accelerated. In this study, we investigated how the presence of AGEs in either non-diabetic or diabetic ECM
affected fibroblast-mediated matrix remodeling. In order to address this question, diabetic and non-diabetic
fibroblasts were embedded in 3D matrices composed of collagen isolated from either non-diabetic or diabetic
mice. Fibroblast function was assessed using gel contraction, migration, and protein expression. Non-diabetic
fibroblasts displayed similar gel contraction to diabetic cells when embedded in diabetic collagen. Thus, sug-
gesting the diabetic ECM can alter fibroblast function from an “inactive” to “active” state. Addition of AGEs
increase the AGE/RAGE cascade leading to increased gel contraction, whereas inhibiting the cascade resulted in
little or no gel contraction. These results indicated 1) the ECM from diabetic and non-diabetic mice differ from
one another, 2) diabetic ECM can impact fibroblast function and shift them toward an “active” state, and 3) that
fibroblasts can modify the ECM through activation of the AGE/RAGE signaling cascade. These results suggested
the importance of understanding the impact diabetes has on the ECM and fibroblast function.
1. Introduction
Individuals with hyperglycemia, seen in type I and type II diabetic
patients, are at an increased risk of developing complications, such as
cardiovascular disease [1]. Left ventricular hypertrophy is a common
cardiovascular complication connected to diabetes resulting in poor
heart function [2,3]. A contributing cause to left ventricular hyper-
trophy is increased cell-mediated remodeling of the myocardial extra-
cellular matrix (ECM) [3]. It has been shown that cardiac tissue from
type II diabetics have increased interstitial ECM accumulation (fi-
brosis), which was attributed to higher numbers of myofibroblasts
present within the heart [3–5]. Cardiac fibroblasts are one of the pre-
dominate cell types of the heart, and they are directly involved in the
synthesis, degradation, and maintenance of the ECM [6]. Cardiac fi-
broblasts are highly responsive to extracellular and intracellular sig-
naling which alters the impact these cells have on the ECM as well as
stimulates cardiac fibroblasts to differentiate into myofibroblasts,
characterized by having higher mobility and contractility that are de-
tected by increased cell migration and elevated expression of α-smooth
muscle action (α-SMA) [4,7,8]. While the extracellular and intracellular
signals mediating myofibroblast transition are becoming better under-
stood, the mechanism by which this occurs is still unclear. Our prior
studies have focused on the AGE/RAGE signaling pathway as a de-
terminant mechanism contributing to fibroblast differentiation into
myofibroblasts in type II diabetes [6]. The current study seeks to build
further on this work in order to develop a better understanding of ex-
tracellular signals stemming from the ECM.
While accumulation of advanced glycation end products (AGEs)
occur naturally over time, their formation and accumulation occur at a
higher and more prevalent rate in diabetic individuals due to hy-
perglycemia [9,10]. Elevated levels of AGEs in the ECM can result in
increased crosslinking of matrix proteins, such as collagen, contributing
to a more rigid ECM [11]. Increased AGE/RAGE signaling can result in
a reduced ECM elasticity impacting tissue physiological function
[6,12]. For example, type I diabetics have an increased level of AGEs
correlated with stiffer heart tissue [12]. In addition, AGEs can induce
intracellular signaling cascades via their receptor, RAGE (receptor for
advanced glycated end products), to stimulate increased growth factor
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secretion as well as collagen synthesis through their downstream in-
teractions with ERK1/2 (p42/p44) MAP kinases [13,14]. AGE/RAGE
signaling also acts in a positive feedback manner resulting in increased
RAGE expression [14]. Activation of AGE/RAGE signaling cascade has
been demonstrated to promote myofibroblast transition which increase
fibrosis leading to the development of left ventricle stiffness and car-
diovascular disease in diabetics [6,15,16].
The combination of glycated ECM, AGE crosslinking, and increased
AGE/RAGE signaling can impact cellular function as well as impair
tissue and organ performance. An elevated presence of ECM AGEs, as
noted with diabetics, has been shown to promote fibroblast to myofi-
broblast transition, which accelerates ECM remodeling [6,17]. For ex-
ample, a study by Fowlkes et al. 2013 demonstrated that diabetic car-
diac fibroblasts embedded in a neutral collagen matrix displayed higher
expression of α-SMA, a marker for myofibroblasts, which contributed to
increased matrix contraction compared to that of non-diabetic fibro-
blasts [3]. While this study examined the role of diabetes in altering
fibroblast phenotype and function in a neutral collagen matrix, it did
not examine the reciprocal impact the ECM composition has on fibro-
blast function. This project aimed to address the gap in knowledge
pertaining to the relationship between the ECM, AGE/RAGE signaling,
and cardiac fibroblasts in type II diabetes. Therefore, we hypothesized
that AGEs within the diabetic ECM will induce myofibroblast transition
via elevated AGE/RAGE signaling resulting in increased remodeling of
the ECM. Utilizing non-diabetic and diabetic cardiac fibroblasts as well
as collagen extracted from diabetic and non-diabetic mice to generate a
3D collagen matrix mimicking in vivo conditions, we were able to as-
sess the changes in fibroblast function and the mechanistic role of AGE/
RAGE signaling.
2. Results
2.1. AGEs within the extracellular matrix induced morphological and
organizational changes in isolated cardiac fibroblasts
In order to examine the impact of AGEs within the extracellular
matrix, diabetic and non-diabetic cardiac fibroblasts were embedded in
a 3D collagen matrix composed of isolated tail collagen from either
diabetic or non-diabetic mice. We found that diabetic tail collagen
contained higher levels of CMLs and AGEs compared to non-diabetic
collagen (Fig. 1A). Elevated levels of AGEs in the diabetic matrix cor-
related with an increased cell aggregation and a flattened cell mor-
phology in both fibroblast genotypes (Fig. 1B). These changes were not
apparent when both cell types were separately placed in a non-diabetic
matrix. For fibroblasts embedded in a diabetic matrix, the addition of
exogenous AGEs to the matrices resulted in an increase in incidents of
morphological changes in cellular phenotypes. AGE-induced morpho-
logical changes were also noted in diabetic cells, and to a lesser degree
in non-diabetic fibroblasts embedded in a non-diabetic matrix, sug-
gesting AGEs in the ECM are capable of influencing fibroblast behavior.
Diabetic matrix-mediated alterations were not limited to changes in
cell morphology and aggregation. Fibroblasts embedded in the 3D
collagen matrix rearranged themselves to form an interconnected net-
work (Fig. 1C). This circular contractile ring structure was primarily
located near the perimeter of the gel matrix, and both non-diabetic and
diabetic fibroblasts formed this contractile ring structure when em-
bedded in diabetic matrices (Fig. 1C: 1Ce & 1Cg) as well as non-diabetic
matrices (Fig. 1C: 1Ca & 1Cc). Within the interconnective network the
fibroblasts extended cellular processes to adjacent cells (Fig. 1C: 1Cb,
1Cd, 1Cf, & 1Ch; white arrowheads), which resulted in cell-cell con-
nections. While both non-diabetic and diabetic fibroblasts formed the
ring structure, the time in which formation occurred differed (Fig. 1D).
Fibroblasts embedded in a diabetic matrix formed the ring structure
1–2 h faster than cells embedded into a non-diabetic matrix.
2.2. Elevated AGE presence in the extracellular diabetic matrix led to
increased fibroblast contraction of collagen matrix
Fibroblasts incorporated into a 3D collagen matrix exerted changes
to the extracellular matrix via contraction. Using similar conditions as
before, diabetic and non-diabetic fibroblasts embedded in a diabetic
matrix displayed significantly more matrix contraction compared to
control (Fig. 2A; one-way ANOVA p = 0.0266). Whereas, prevention of
ERK activation with U0126, which directly inhibits upstream proteins
MEK1 and MEK2, reduced the amount of matrix contraction, but the
amount of matrix contraction was still significantly more than U0126
treated control (Fig. 2B; one-way ANOVA p = 0.0028). Non-diabetic
and diabetic fibroblasts significantly increased matrix contraction when
embedded in a diabetic matrix treated with exogenous AGEs (Fig. 2C,
one-way ANOVA p = 0.0045). Treatment with both AGEs and U0126
produced results similar to U0126 treated matrices (Fig. 2D; one-way
ANOVA p = 0.0837). The results, taken together, suggested that in-
creased AGEs in the ECM caused fibroblasts to undergo increased ma-
trix contraction.
2.3. Increased exogenous AGEs in diabetic matrices led to significantly
elevated α-SMA and RAGE protein expression in cardiac fibroblasts
Changes in fibroblast morphology, organization, and function can
be linked to fibroblasts that have transitioned into an “active” fibroblast
(i.e. myofibroblast), and this transition can be assessed by examination
of changes in α-SMA protein expression (Fig. 3A-D). Non-diabetic fi-
broblasts in both non-diabetic and diabetic matrix expressed lower le-
vels of α-SMA in untreated as well as in U0126 treated cells (Fig. 3A,
one-way ANOVA p < 0.0001; Fig. 3B, one-way ANOVA p = 0.0640).
When cardiac fibroblasts were treated with exogenous AGEs, non-dia-
betic fibroblasts embedded in a diabetic matrix expressed significantly
more α-SMA compared to similar cells in a non-diabetic matrix (Fig. 3C;
one-way ANVOA p < 0.0001, Dunnett's post hoc p = 0.0113).
Treatment with both U0126 and AGEs led to an increase in α-SMA in
non-diabetic fibroblasts in a diabetic matrix compared to cells em-
bedded in a non-diabetic matrix but the increase was not to the same
level as seen in those treated with AGEs alone (Fig. 3D; one-way
ANOVA p = 0.0162).
Examination of untreated diabetic fibroblasts showed significantly
more expression of α-SMA compared to the control (Fig. 3A; Dunnett's
post hoc p < 0.0001). The expression of α-SMA was lower in diabetic
fibroblasts in a diabetic matrix treated with U0126 (Fig. 3B; one-way
ANOVA p = 0.0640). Whereas treatment with AGEs resulted in a sig-
nificant increase in α-SMA expression in diabetic fibroblasts in a dia-
betic matrix compared to AGE treated control group (Fig. 3C; Dunnett's
post hoc p < 0.0001). Combined treatment of U0126 and AGEs re-
sulted in a significant increase, but not to the same level as seen with
AGE treatment alone, in α-SMA expression in diabetic fibroblasts em-
bedded in a diabetic matrix (Fig. 3D; Dunnett's post hoc p = 0.0199).
These results suggested that increased AGEs in the ECM induced an
increased fibroblast to myofibroblast transition. In addition to ex-
amining α-SMA expression, RAGE expression was assessed.
RAGE expression can be upregulated through a positive feedback
loop with AGE/RAGE signaling. RAGE expression in non-diabetic fi-
broblasts embedded in non-diabetic and diabetic matrices were un-
changed (Fig. 3E; one-way ANOVA p=0.0015). Treatment with U0126
did not impact RAGE expression in non-diabetic fibroblasts in non-
diabetic or diabetic matrices (Fig. 3F; one-way ANOVA p = 0.0006).
RAGE expression significantly increased when treated with exogenous
AGEs in non-diabetic fibroblasts in a diabetic matrix compared to the
AGE treated control (Fig. 3G; one-way ANOVA p = 0.0169, Dunnett's
post hoc p = 0.0115). U0126 and AGE combined treatment resulted in
low RAGE expression in non-diabetic fibroblasts in both non-diabetic
and diabetic matrices (Fig. 3H).
In contrast to non-diabetic fibroblasts, diabetic fibroblasts displayed
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significantly higher RAGE expression when embedded in both non-
diabetic and diabetic matrices compared to the control (Fig. 3E; one-
way ANOVA p = 0.0015). This pattern of elevated RAGE expression
remained the same with treatment of U0126. Diabetic fibroblasts in
non-diabetic and diabetic matrices exhibited significantly higher RAGE
expression compared to U0126 treated control (Fig. 3F; one-way
ANOVA p = 0.0006). Treatment with AGEs led to a significantly
greater RAGE expression in diabetic fibroblasts in non-diabetic and
Fig. 1. AGEs within the extracellular matrix induced morphological and organizational changes in isolated cardiac fibroblasts. A) Immunofluorescence staining
(100×; scale bar = 50 μm) revealed elevated levels of carboxymethyl lysine (CML) and advanced glycation end-products (AGEs) in diabetic collagen matrices absent
of fibroblasts. B) Bright field images (100×; scale bar = 100 μm) of non-diabetic (non-db) and diabetic (db) cardiac fibroblasts embedded in collagen matrices from
non-db or db mice. Matrices treated with exogenous AGEs had higher numbers of flattened cell morphology (black arrowheads) as well as increased cell aggregation
(red asterisks). C) Non-db and db fibroblasts in collagen matrices were labeled with phalloidin (actin-cytoskeleton, red) and DAPI (DNA-nuclei, blue). Fibroblasts
appeared to organize into connecting ring structures within the collagen matrix (100×; scale bar = 100 μm). Boxes indicate areas of interest at 200×, white arrows
indicate cellular connections between fibroblasts. D) Bright field images (40×) were taken to demonstrate the time course for cardiac fibroblasts (non-db and db) to
form initial ring structures in non-db and db matrices. Dashed black lines and red arrows indicate initial cell ring organization. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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diabetic matrices compared to AGE treated control (Fig. 3G; one-way
ANOVA p = 0.0169). However, the overall expression of RAGE in
diabetic fibroblasts was lower with AGE treatment compared to diabetic
fibroblasts in untreated and U0126 treatment. Combined U0126 and
AGE treatment resulted in lower RAGE expression in diabetic fibro-
blasts in a non-diabetic matrix and did not significantly differ from the
U0126 and AGE treated control (Fig. 3H; one-way ANOVA
p < 0.0001). Whereas diabetic fibroblasts in a diabetic matrix treated
with U0126 and AGEs did significantly express more RAGE than non-
diabetic fibroblasts in non-diabetic matrix (one-way ANOVA
p < 0.0001, Dunnett's post hoc p < 0.0001). Inhibition of RAGE
signaling through pharmacological means had a broad impact on AGE/
RAGE-mediated matrix contraction and protein expression; however,
further studies were undertaken to determine if genetic knockdown of
RAGE directly inhibited AGE/RAGE signaling and matrix contraction in
cardiac fibroblasts.
Fig. 2. Elevated AGE presence in the extracellular diabetic matrix led to increased fibroblast contraction of collagen matrix. Non-diabetic (non-db) and diabetic (db)
fibroblasts were embedded in non-db and db matrices. Matrix contraction for A) Untreated, B) U0126 treated (5 μM), C) AGE treated (0.5 mg/mL), and D)
AGE + U0126 treated matrices were determined by measuring the area of the fibroblast contractile ring and normalized to the area of the contractile ring from non-
db fibroblasts embedded in non-db matrix. Control was set a 0 with a positive value indicating less matrix contraction (larger ring area) while a negative value
denotes more matrix contraction (smaller ring area). Representative matrix images, displayed above graphs, were from the same plate but arranged in a different
order to match graph depiction. Data are mean ± SEM, n = 7–10, and statistical analysis consisted of a one-way ANOVA followed by a Dunnett's post hoc
(*p < 0.05, **p < 0.01, ***p < 0.001).
Fig. 3. Increased exogenous AGEs in diabetic matrices led to significantly elevated α-SMA and RAGE protein expression in cardiac fibroblasts. Quantification of
western blot analysis for α-SMA (42 kDa; A-D) and RAGE (43 kDa; E-H) protein expression was normalized to total protein (Coomassie stain) in untreated, U0126
treated (5 μM), AGE treated (0.5 mg/mL), and AGE + U0126 treated matrices. Data are means± SEM with n = 3–6 of independent repeats. Representative western
blot images shown above figures are not displayed as a continuous blot due to running order, but all were run on the same blot. Statistical analysis consisted of a one-
way ANOVA with a Dunnett's post hoc (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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2.4. Knockout of RAGE signaling prevented AGE-induced fibroblast matrix
contraction in diabetic matrix
Knocking out RAGE prevented the impact of diabetic matrix and
AGEs on fibroblast function. Cardiac fibroblasts isolated from RAGE
knockout mice (RKO) were embedded into non-diabetic and diabetic
matrices and matrix contraction was determined and compared to non-
diabetic fibroblasts that have a functioning RAGE receptor (data pre-
viously shown in Fig. 2). As shown previously, non-diabetic fibroblasts
with functioning RAGE embedded in a diabetic matrix exhibited sig-
nificantly more matrix contraction in both U0126 treated (Fig. 4A; one-
way ANOVA p= 0.0344, Sidak's post hoc p= 0.0124) and AGE treated
(Fig. 4B; one-way ANOVA p = 0.0004, Sidak's post hoc p = 0.0001)
matrices compared to the control. Non-diabetic fibroblasts also dis-
played slightly more, but not significantly different, matrix contraction
when treated with both U0126 and AGE (Fig. 4C; one-way ANOVA
p = 0.1809, Sidak's post hoc p = 0.1124). In contrast, non-diabetic
RKO fibroblasts embedded in diabetic matrices did not display sig-
nificant increases in matrix contraction when treated with U0126 (Si-
dak's post hoc p = 0.5112), AGE (Sidak's post hoc p = 0.5804), or
AGE + U0126 (Sidak's post hoc p = 0.6359) compared to non-diabetic
matrices containing RKO fibroblasts (Fig. 4). This data suggested that
inhibition of AGE/RAGE signaling in cardiac fibroblasts prevented the
amount of matrix contraction otherwise noted in fibroblasts with intact
functioning RAGE.
2.5. Knockout of RAGE prevented increases in α-SMA expression in
exogenously AGE treated matrices
α-SMA expression from non-diabetic RKO fibroblasts embedded into
non-diabetic and diabetic matrix was compared to non-diabetic fibro-
blasts with RAGE (previously shown in Fig. 3). As shown previously,
non-diabetic fibroblasts with RAGE exhibited low α-SMA expression in
control and U0126 treated groups (Fig. 5A&B). AGE treatment caused a
significant increase in α-SMA expression in non-diabetic fibroblasts in a
diabetic matrix compared to those embedded into a non-diabetic matrix
(Fig. 5C; one-way ANOVA p = 0.0141, Sidak's post hoc p = 0.0086). A
similar, but not significant, increase in α-SMA expression was noted in
non-diabetic fibroblasts in a diabetic matrix compared non-diabetic
matrix when treated with both AGE and U0126 (Fig. 5D). Contrary to
these results, non-diabetic RKO fibroblasts did not display a significant
increase in α-SMA expression in controls (Sidak's post hoc p = 0.9994),
U0126 treated (Sidak's post hoc p = 0.6474), AGE treated (Sidak's post
hoc p = 0.9863) or combined U0126 + AGE treated (Sidak's post hoc
p = 0.8219) when embedded in a diabetic matrix compared to being
embedded into a non-diabetic matrix (Fig. 5). Western blot analysis for
RAGE expression was done for non-diabetic RKO fibroblasts embedded
in non-diabetic and diabetic matrices but was not detected due to RAGE
being knocked out in these animals (DOI: https://doi.org/10.6084/m9.
figshare.11299253). These results indicated that AGE/RAGE signaling
is responsible for myofibroblast transition induced by AGEs in the ECM.
3. Discussion
The results presented in this study demonstrated that a reciprocity
exists in which the elevated presence of AGEs in the ECM can 1) act in a
signal transduction manner to amplify the cardiac fibroblast to myofi-
broblast phenotype transition through the RAGE cascade and 2) change
cellular function to outwardly modify the surrounding ECM resulting in
increased matrix contraction. The results presented in this study in-
dicate that elevated presence of AGEs in the diabetic ECM induce fi-
broblasts to transition into myofibroblasts, and this transition is noted
by increased α-SMA expression and greater matrix contraction.
3.1. The impact of the ECM on cardiac fibroblasts
A higher prevalence of AGE-crosslinked collagen in the ECM greatly
impacted cardiac fibroblast morphology and organization. Elevated
AGE levels have been demonstrated to occur in individuals with dia-
betes due to chronic hyperglycemia [9,18]. As we reported, collagen
extracted from diabetic mice had higher concentrations of AGEs and
CMLs compared to collagen isolated from non-diabetic counterparts.
Increased levels of AGEs present in the collagen can impact ECM
structural properties by reducing matrix elasticity and thus increased its
stiffness [19,20]. The physical presence of AGEs and changes in matrix
properties perpetuated by AGEs was shown to induce morphological
changes in embedded cardiac fibroblasts. When both non-diabetic and
diabetic cardiac fibroblasts were exposed to higher levels of AGEs, as
those present in diabetic matrices, there were increased cell aggrega-
tion as well as a higher number of cells displaying a more flatten
Fig. 4. Knockout of RAGE signaling prevented AGE induced fibroblast matrix contraction in diabetic matrix. Non-diabetic (non-db) and non-diabetic RAGE knockout
(non-db RKO) fibroblasts were embedded in non-db and db collagen matrices. Area of the contractile ring for each treatment group (A:U0126 [5 μM], B:AGE [0.5 mg/
mL], and C:AGE + U0126 treated) were measured and normalized to the ring area of the genotypic control on non-db matrix. Contraction of the control treatment
was set a 0 with positive values indicating decreased contraction (larger ring area) and a negative value indicating increased matrix contraction (smaller ring area).
Pictures are representative of matrix images for each treatment group (images are from same plate and gaps are due to proper alignment of images with graphs) and
images for non-diabetic fibroblasts with functional RAGE were used in Fig. 2. Data are mean ± SEM, n = 6–10. Statistical significance determined by one-way
ANOVA followed by a Sidak's post hoc (*p < 0.05, ***p < 0.001).
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morphology. These physical changes were considered to be a result of
increased AGEs within the matrices triggering activation of the RAGE
signaling cascade. In fact, treatment of diabetic fibroblasts in non-dia-
betic matrices with AGEs led to increased changes is cell aggregation
and morphology. Previous studies have demonstrated that treatment
with AGEs accelerated the epithelial-myofibroblast transition and in-
duced a flatten fibroblast morphology described as a myofibroblast
[21]. While the presence of AGEs in the ECM can induce physical
changes in cardiac fibroblasts, they also promoted organizational
changes [22,23].
Elevated AGEs in the ECM caused changes in cardiac fibroblast or-
ganization within the 3D collagen matrix. Non-diabetic and diabetic
cardiac fibroblasts formed an interconnective network within the ma-
trix, referred to as a contractile ring. The formation of the contractile
ring structure occurred in every treatment group; however, the rate at
which it formed was accelerated when cells were embedded in diabetic
conditions. Diabetic fibroblasts also formed the contractile ring struc-
ture faster than non-diabetic fibroblasts. Other labs have previously
demonstrated that diabetic cardiac fibroblasts migrate faster than non-
diabetic fibroblasts when plated on neutral collagen [3]. The increased
migration noted in diabetic fibroblasts in our studies may have led to
faster formation of the contractile ring structure. Interestingly, we
found the formation of the contractile ring occurred more rapidly when
fibroblasts, both non-diabetic and diabetic, were embedded in a dia-
betic matrix. One plausible explanation for increased migration is that
diabetic matrices contain elevated amounts of AGEs, which could in-
duce AGE/RAGE signaling within the cardiac fibroblasts leading cells
toward myofibroblast differentiation [24]. A study by Vicens-Zygmunt
et al. 2015 showed lung fibroblasts embedded in AGE-crosslinked ma-
trices had increased α-SMA expression, indicating increased myofi-
broblast population [25]. Thus, lending support to our findings, that
AGEs within the diabetic matrix can induce myofibroblast transition via
RAGE signaling resulting in increased migration and contractile ring
formation. While the composition of the ECM can act as an inward
signaling stimulus to impact fibroblast function, it also can activate
fibroblasts to outwardly modify their surrounding environment.
3.2. The impact of cardiac fibroblasts on the ECM
While diabetic cardiac fibroblasts exhibited greater overall matrix
contraction, this phenomenon occurred when diabetic cells were placed
in either non-diabetic or diabetic collagen matrices. Thus, demon-
strating these cells possess “programmed” capable of orchestrating al-
terations to both non-diabetic and diabetic matrices. This ability could
be attributed to the cell characteristics retained from the diabetic in
vivo environment, meaning cardiac fibroblasts from a diabetic animal
may have been primed to more easily transition to a myofibroblast
phenotype. Previous studies have demonstrated that diabetic cardiac
fibroblasts embedded in a 3D matrix have higher expression of α-SMA
[3]. Therefore, higher α-SMA expression levels was used as an indicator
of growing myofibroblasts populations, and functionally, these cells
were characterized by increased contractility [7]. With increased con-
traction as noted in earlier experiments, diabetic fibroblasts could more
readily differentiate into myofibroblasts [7]. Additionally, we observed
that non-diabetic fibroblasts embedded in a diabetic matrix displayed
comparable matrix contraction to that of diabetic fibroblasts embedded
in a diabetic matrix. This increased contraction was not dependent on
the presumed stiffness of the diabetic matrix. Howard et al. 1996
showed glycated matrices displayed less contractility than their non-
glycated counterparts, and these researchers attributed matrix stiffness
to decreased contraction [26]. Our data suggests that matrix stiffness
was not the driving force behind increased contraction, but rather
changes were due to AGEs within the matrix causing increased RAGE
signaling in the cardiac fibroblasts. Further studies will need to be
performed to determine if changes in rheological properties of the
matrices impact fibroblast behavior.
When non-diabetic and diabetic fibroblasts were embedded in a
diabetic matrix the combined exposure to AGEs present in the diabetic
collagen and to exogenous AGE treatments increased activity of the
AGE/RAGE signaling cascade resulting in a significant rise in con-
tractility. Interruption of the AGE/RAGE signaling axis with prevention
of ERK1/2 activation, via U0126 inhibition MEK 1 & 2, reduced the
levels of matrix contraction in non-diabetic cells in both matrix types as
well as diabetic fibroblasts in non-diabetic matrix. Phosphorylation of
ERK1/2 is not limited to activation of AGE/RAGE signaling; however,
matrix contraction was most likely not influenced by other signaling
cascades. Considering the results noted in studies when cells, treated
with combined AGE and U0126, had reduced matrix contraction even
in the presence of exogenous AGEs. While long exposure to exogenous
AGEs should have overcome U0126 inhibition due to half-life of drug
activity, we observed contraction occurred early in the matrix re-
modeling process. We speculate ERK1/2 is activated rapidly during fi-
broblast matrix contraction, and U0126 treatment during this critical
period prevented AGE-induced matrix contraction [27]. While ERK1/2
inhibition reduced matrix contraction in most groups, diabetic fibro-
blasts in a diabetic matrix retained greater matrix contraction despite
U0126 treatment. Thus, indicating there was more AGE/RAGE sig-
naling within diabetic cells to potentially override ERK1/2 inhibition
and induce matrix contraction. Alternatively, we observed RAGE KO
cells had reduced matrix contraction. Knocking out RAGE signaling in
Fig. 5. Knockout of RAGE prevented increases in α-SMA-expression in exogenous AGE treated matrices. Non-diabetic (non-db) and non-diabetic RAGE knockout
(non-db RKO) fibroblasts were embedded in non-db and db matrices. α -SMA (42 kDa) expression was assessed via western blot analysis and normalized to total
protein (Coomassie stain) for A) untreated, B) U0126 treated (5 μM), C) AGE treated (0.5 mg/mL), D) and AGE+ U0126 treated. Representative western blot images,
depicted above graph, are not presented as a continuous blot due to the order of the graph but were run on the same western blot. Western blot images for non-
diabetic fibroblasts were also presented in Fig. 3. Data are mean ± SEM with n = 3–5 independent repeats for each group. One-way ANOVA with Sidak's post hoc
determined significant difference (*p < 0.05).
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cardiac fibroblasts restored matrix contraction to levels noted in control
cells (non-diabetic fibroblasts embedded in a non-diabetic matrix). In-
dicating AGE/RAGE signaling is a key mechanism responsible for in-
creased matrix contraction and myofibroblast differentiation.
AGE treated diabetic and non-diabetic fibroblasts embedded in
diabetic matrices displayed significantly more α-SMA protein expres-
sion than controls. Changes in α-SMA expression did not occur when
fibroblasts were treated with U0126 or in RKO fibroblasts, indicating
elevated AGE/RAGE signaling denotes increased myofibroblast transi-
tion. Additional to marking myofibroblast presence, increased levels of
α-SMA suggested changes to the contractile apparatus had occurred
within a cell. Previous studies have demonstrated increased expression
of α-SMA correlated with increased matrix contraction [28,29]. While
non-differentiated cardiac fibroblasts are able to contract the collagen
matrix, additional matrix contraction, past that of “normal” re-
modeling, would require the presence of myofibroblasts [30]. In addi-
tion to α-SMA expression, we examined RAGE expression within the
treatment groups. RAGE expression is regulated by a positive feedback
loop where increased RAGE signaling results in increased RAGE ex-
pression [31]. There was elevated RAGE expression in diabetic fibro-
blasts compared to non-diabetic fibroblasts in most treatment groups.
These findings suggest diabetic fibroblasts maintained an elevated level
of RAGE expression within the in vitro cell culture model, which was
mostly likely similar to that found in an in vivo setting [32]. The higher
expression of RAGE in diabetic fibroblasts represents a maintenance of
an in vivo phenotype, since RAGE is elevated with diabetes [6]. The
preservation of RAGE expression in diabetic fibroblast cultures could
also explain the significantly higher α-SMA expression levels found in
untreated diabetic fibroblasts embedded in a diabetic matrix [33].
Though RAGE expression was high in diabetic cells treated with U0126,
it did not translate into elevated levels of α-SMA. This is due to U0126
effectively inhibiting the AGE/RAGE signaling cascade in these diabetic
cells and prevented an increase in α-SMA (i.e. myofibroblast transition).
The key findings of this study indicated elevated levels of AGEs
within the ECM, as observed in diabetics, can induce fibroblast to
myofibroblast transition resulting in increased matrix contraction
marked by elevated α-SMA expression. High levels of AGEs in diabetic
matrices induced morphological changes in both non-diabetic and
diabetic cardiac fibroblasts. These physical changes, in combination
with organizational rearrangements, resulted in greater matrix con-
traction that was due to increased myofibroblast transition [7]. In-
hibition of AGE/RAGE signaling via pharmacological methods as well
as a knockout RAGE model prevented increased matrix contraction and
fibroblast differentiation. Overall, this study highlights the reciprocal
relationship between the ECM and cardiac fibroblasts under diabetic
conditions in which increased AGE presence caused a shift in fibroblast
phenotype to impact matrix contraction. Utilizing these results, we can
gain a better understanding of how cardiac fibroblasts exposed to ele-




Experiments were conducted using 16 week old male Leprdb (db/db)
type II diabetes mellitus mice (BKS.Cg-Dock7m +/+ Leprdb/J, Jackson
Labs) and heterozygous mice (db/wt; non-diabetic) were used as lean
controls. The Leprdb mice have a point mutation in the leptin receptor,
resulting in a nonfunctional receptor. The loss of function of the leptin
receptor leads to obesity and insulin resistance, which manifests into
hyperglycemia by 8 weeks of age and diabetes by 12 weeks of age. In
addition, 16 week old male non-diabetic homozygous RAGE knockout
mice (RKO) were used for this study. RKO mice were generated by
flanking exons 2–7 with two loxP sites in the same orientation and when
exposed to Cre recombinase, the loxP and exons 2–7 were deleted
[34–36]. This results in a loss of global RAGE mRNA expression and in
turn RAGE signaling in these mice. In addition, a reversely-oriented
transcriptional EGFP reporter gene was inserted into intron 1, which is
used as a positive control for RAGE knockout mice [34–36]. Breeder
RKO mice were a generous gift from Dr. Pamela Lucchesi and Dr. An-
gelika Bierhaus. All mice were housed with 12 h/12 h light/dark cycle
and were fed standard chow and tap water ad libitum. All experiments
followed the guidelines of the National Institutes of Health “Guide for
the Care and Use of Laboratory Animals,” and protocols (protocol
#17–024) were approved by The University of Mississippi IACUC
committee. Mice were anesthetized with CO2 exposure followed by
cervical dislocation. After anesthetization, body weight and blood
glucose measurements were taken followed by quick excision of the
heart, which was used for cellular experiments (Table 1).
4.2. Fibroblast isolation and culture
Cardiac fibroblasts were isolated from hearts via collagenase-trypsin
enzymatic solution (0.1% Trypsin, Gibco; 100 U/mL collagenase II,
Worthington Biochemical) [6]. Three hearts were used per one fibro-
blast isolation, whereby one isolation equaled one sample (n = 1).
Fibroblasts were cultured in DMEM media (Dulbecco's Modified Eagles
Medium [DMEM], sodium pyruvate, L-glutamine, and supplemented
with 14.2 mM NaHCO3, 14.9 mM HEPES, 15% heat-inactivated fetal
bovine serum [FBS], 1% L-glutamine, and 0.02% Primocin [Thermo
Fisher]) and specifically non-diabetic fibroblasts were cultured in low
glucose DMEM (1 g glucose/L) and diabetic fibroblasts in high glucose
DMEM (4.5 g glucose/L). Fibroblasts were maintained in 5% CO2 in-
cubator at 37 °C. Cells were passaged just prior to reaching 95% con-
fluency using 0.25% trypsin, 0.1% ethylenediaminetetraacetic acid
(trypsin/EDTA) solution (Life Technology). Passage 1 fibroblasts were
used in experiments and were serum starved (0.01% FBS) for 24 h
before use. For this study the descriptive terms diabetic and non-diabetic
associated with the cells used in this study are used to delineate the
source of the fibroblasts and does not imply they are diabetic or non-
diabetic.
4.3. Collagen extraction
Collagen was extracted from tails from 16 week old non-diabetic
and diabetic mice [37]. Tails were collected at time of euthanasia and
stored at -20 °C until use. The skin was removed from the tail to expose
the 4 major tendons. Tendons were removed and placed in 150 mL
acetic acid (1:1000 dilution in dH2O) and were cut into small ~5 mm
pieces. The tendon solution was mixed for 3 days at 4 °C. All steps,
hereinafter, were conducted in sterile conditions. After 3 days, the
tendon-acetic acid solution was centrifuged at 3000 xg for 30 min at
4 °C to pellet debris. Supernatant was removed and centrifuged, again,
under the same conditions. The collagen supernatant was removed and
stored at 4 °C. Collagen concentration was estimated using Sircol™
Soluble Collagen Assay Kit (Biocolor Ltd) as per manufacturer's
Table 1
Physiological measurements of mice used in in vitro experiments. Data consists
of average values from mice that were used to isolate cardiac fibroblasts with an
average of 2–3 hearts per isolation. Statistical analysis using a one-way ANOVA
followed by a Dunnett's post hoc determined significance difference compared
to non-diabetic mice (*p < 0.05, ****p < 0.0001).
Body weight (g) Blood glucose
(mg/dL)
Heart weight (mg)
Non-diabetic 28.32 ± 0.55 232 ± 7.9 0.104 ± 0.002
Diabetic 50.09 ± 1.23 **** 519 ± 24.4 **** 0.120 ± 0.008
Non-diabetic
RKO
31.64 ± 0.67 * 220 ± 5.8 0.113 ± 0.004
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directions.
4.4. 3-Dimensional collagen matrix
Collagen discs were prepared by slowly combining collagen
(2.9 mg/mL), 10× minimum essential media (MEM, Thermo Fisher),
and 0.2 M HEPEs on ice in an 8:1:1 ratio [38]. This was done for both
non-diabetic and diabetic collagen. The collagen solution was placed on
ice in a desiccator and degassed for 10 min to remove air bubbles.
Following removal of air bubbles, equal volumes of the collagen solu-
tion and fibroblast cell suspension were combined. The collagen solu-
tion containing fibroblasts was plated 1 mL of solution per well in a 24
well plate. Collagen/fibroblast solution was incubated for 1 h at 37 °C
to allow the 3D collagen matrix to polymerize in a disc. After matrix
polymerization, the collagen disc was dislodged from the sides of the
well and 1 mL of starving media was added to each well. AGE (0.5 mg/
mL, Sigma Aldrich) and U0126 (5 μM, Sigma Aldrich) were added to
the appropriate well and was incubated for 7 days at 37 °C. During the
incubation period, the media was not changed, and no additional do-
sage of drugs occurred. Again, we have chosen to use the descriptive
terms diabetic and non-diabetic with the extracellular matrix collagen in
this study to define the source of the matrices and does not imply they
are diabetic or non-diabetic.
4.5. Matrix contraction analysis
Matrix images were captured using an iBRIGHT imaging system
(Thermo Fisher Scientific) with a ruler for scale reference. Capture
specifications were set: Zoom: 1.2 and Focus: 2.16. Image J software
(NIH) was used to measure the area of the ring structure. The ring area
was determined to be the space from the center of the circular ring to
the inner perimeter of the ring structure. The scale for each image was
set using the ruler included in the image. Ring area for each sample was
normalized to the “control” which was designated as the average ring
area exhibited by untreated, non-diabetic fibroblasts in non-diabetic
matrix (n = 9). This group was selected as the “control” because it best
represented how fibroblasts would normally act when embedded into a
collagen matrix. The “control” value used to normalize other treatment
groups. The control value was determined by averaging the ring area of
all the untreated non-diabetic fibroblasts in a non-diabetic matrix va-
lues together to generate one “control” value. This value was then used
to normalize the other treatment groups.
4.6. Western blot analysis
Protein was isolated from matrices using modified Hunter's buffer
(MHB; 1% Trition X-100, 75 mM NaCl, 5 mM tris pH 7.4, 0.5 mM or-
thovanadate, 0.5 mM ECTA, 0.5 mM EGTA, 0.25% NP-40, and freshly
added Halt Protease Inhibitor Cocktail (100×; Thermo Fisher)).
Matrices were incubated on ice with MHB for 10 min, followed by
probe-sonication. Samples were centrifuged for 15 min at 32,000 xg at
4 °C, sonicated again, and then centrifuged at same conditions as be-
fore. Repeated sonication was necessary to ensure the matrix was dis-
rupted to yield high protein concentrations. Protein concentration was
determined using a bicinchoninic acid assay (BCA; Pierce
Biotechnology) according to manufacturer's instructions. 20 μg of pro-
tein was used per sample for western blot analysis. Antibodies used
were as follow: monoclonal α-smooth muscle actin (α-SMA (1:400);
Sigma Aldrich 2547) and RAGE ((1:400) Santa Cruz sc-365,154).
Coomassie stain was used to label total protein and as a loading control
[39,40]. Western blots were visualized using an iBRIGHT imaging
system and Image J was used for analysis.
4.7. Immunofluorescence
Collagen matrices, with or without fibroblasts, were fixed with
histology grade 4% paraformaldehyde (Fisher Scientific). Fibroblasts
and matrix were incubated in blocking solution (3% donkey serum
[Fisher Scientific], 2% BSA [Fisher Scientific], 0.01% Trition X-100 in
1× PBS) overnight at 4 °C. Primary antibody was added to matrix and
incubated overnight at 4 °C. Advanced glycated end product (AGE)
antibody (1:50; Abcam ab23722) and carboxymethyl lysine (CML)
antibody (1:50; Abcam ab30917) were added to matrices without cells.
Directly conjugated phallodin-cy3 (1:20; Thermo Fisher) was added to
matrices with embedded fibroblasts. After primary antibody incuba-
tion, matrices with fibroblasts had DAPI (1:1000; Fisher Scientific)
added for 1.5 h at room temperature in the dark in order to visualize the
nucleus. Matrices were imaged using a Nikon Eclipse Ti2 microscope
with pco.edge camera (PCO).
4.8. Statistical analysis
Graph Prism software, version 8.1.1 was used for statistical analysis.
A one-way ANOVA was conducted for the data presented in Figs. 2-5
and was followed by a post hoc to determine significance between
specific experimental groups. Data focusing on differences between
non-diabetic and diabetic fibroblasts (Figs. 2 & 3) used a Dunnett's post
hoc. The Dunnett's post hoc was chosen because our interest was in
comparing the different experimental groups back to the “control”
group which was non-diabetic fibroblasts in a non-diabetic matrix.
Experiments focusing on the impact of RAGE knockout (RKO) on car-
diac fibroblasts (Figs. 4 & 5) used a Sidak post hoc. The Sidak post hoc
was used due to the interest of only comparing significance between the
same cell type (non-diabetic or non-diabetic RKO fibroblasts) on dif-
ferent matrices.
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